Waverly Advisors LLC Has $24.72 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Waverly Advisors LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 84.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,016 shares of the company's stock after buying an additional 14,676 shares during the quarter. Waverly Advisors LLC's holdings in Eli Lilly and Company were worth $24,716,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Whelan Financial raised its stake in shares of Eli Lilly and Company by 6.1% in the fourth quarter. Whelan Financial now owns 484 shares of the company's stock valued at $374,000 after acquiring an additional 28 shares during the last quarter. Williams Jones Wealth Management LLC. increased its holdings in Eli Lilly and Company by 5.9% during the 4th quarter. Williams Jones Wealth Management LLC. now owns 28,693 shares of the company's stock valued at $22,151,000 after purchasing an additional 1,611 shares in the last quarter. Victrix Investment Advisors bought a new position in Eli Lilly and Company in the 4th quarter valued at $936,000. Vident Advisory LLC boosted its stake in Eli Lilly and Company by 16.0% in the fourth quarter. Vident Advisory LLC now owns 32,617 shares of the company's stock worth $25,182,000 after purchasing an additional 4,500 shares in the last quarter. Finally, Vienna Asset Management LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $1,254,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Down 0.2%

LLY traded down $1.21 during trading hours on Friday, hitting $713.99. 2,631,160 shares of the company's stock were exchanged, compared to its average volume of 3,615,016. The stock has a market cap of $676.67 billion, a price-to-earnings ratio of 60.97, a PEG ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The stock's 50-day moving average is $789.29 and its two-hundred day moving average is $803.00. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same period last year, the firm earned $2.58 earnings per share. The company's quarterly revenue was up 45.2% compared to the same quarter last year. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.84%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Analysts Set New Price Targets

LLY has been the subject of a number of research analyst reports. Truist Financial lifted their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Cantor Fitzgerald began coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.